Summary papers outlining the findings of a global consensus report into presbyopia have been published by the British Contact ...

Eye-focused biotechs Tenpoint Therapeutics and Visus Therapeutics are joining forces, setting their sights on filing a new drug approval application next year for a presbyopia-correcting eye drop.

Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US, and seems to be becoming more of a ...

Press Release Tenpoint Therapeutics, Limited ("Tenpoint") and Visus Therapeutics, Inc., ("Visus") announce today the completion of their merger to create an entirely new chapter in ophthalmic ...

UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at ...

Rising Prevalence: The increasing prevalence of myopia and presbyopia, particularly in urban areas and among aging populations, is a key driver of market expansion. In regions like Asia, where myopia ...

India's medical fraternity drove creative and cost-effective innovations, making 2024 a landmark year for medical ...

Maintaining eye health as you age requires a proactive approach combining good habits and regular checkups By eating a ...

The company will file the NDA for BRIMOCHOL™ PF, a once-a-day eye drop for the treatment of presbyopia, with a goal of US commercial launch in 1H, 2026 Merger initiates Crossover Financing Round with ...

Lento Bio Inc. has synthesized cysteine derivatives reported to be useful for the treatment of presbyopia. An exemplified compound (Cpd in row 4 in tbl1 pg 20, claim 18) decreased in lens stiffness in ...